IMC 1.18% 8.6¢ immuron limited

Ann: Annual Report to shareholders, page-28

  1. 2,019 Posts.
    lightbulb Created with Sketch. 315
    The Company intends to use the net proceeds from this offering to fund Immuron’s
    Research and Development, preclinical and clinical programs, support marketing initiatives
    surrounding the Company’s flagship product Travelan and provide ongoing working capital for the
    Company.
    apparently
 
watchlist Created with Sketch. Add IMC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.